STAFF BOARD
Article
CHAIRMAN
Manuela Velázquez Prieto
EDITOR IN CHIEF
Jaime E. Poquet Jornet
MARKETING MANAGER
Margarita Pamplona
EDITORIAL BOARD
Tomás Casasín Edo
Virginia Hernández Corredoira
Ramón Jódar Masanés
Juan Carlos Juárez Giménez
Volume 19 - Issue 2, March-April 2017
ORIGINAL
ANALYSIS OF TREATMENT FAILURE WITH STANDARD AND HIGH DOSE OF TIGECYCLINE IN CRITICALLY ILL PATIENTS WITH MULTIDRUGRESISTANT BACTERIA
RUIZ JESÚS, PÉREZ-HUERTAS PABLO, VILLARREAL ESTHER, GORDON MÓNICA, QUINZÁ ADRIÁN, RAMÍREZ PAULA


Objectives: The emergence of multidrug-resistant (MDR) bacteria has created a challenge in the treatment of nosocomial infection. Serious concern has risen regarding the possible treatment failure with the standard tigecycline regimen. The aim of this study is to describe tigecycline outcomes in critically ill patients and to
identify possible factors related with tigecycline treatment failure.

Method: We designed a retrospective study. Critically ill patients infected by MDR gram negative bacteria who received tigecycline from January 2010 to March 2016 were included. Primary endpoints were clinical and microbiological outcomes and 30-day mortality. Differences between high (100 mg/12h) and standard (50 mg/12h) dose in main outcomes were evaluated.

Results and discussion: 46 patients were included in the analysis, 38 (78.3%) of them had received previous antimicrobial therapy. Clinical response was observed in 19 (41.3%) patients and clinical failure in 23 (50%). Mortality rate at day 30 was 39.3% (No. = 18). No significant differences were found in clinical or
microbiological treatment failure and in 30-day mortality between high dose and standard dose. In the multivariate analysis, neutropenia was significantly associated with 30-day mortality [OR: 7.66 (1.53-38.32)] and clinical failure [OR: 5.44 (0.96-30.77)].

Conclusion: Treatment with tigecycline in critical patients previously treated with other antibiotics is associated with a high risk of treatment failure. Benefit and risk should be considered, especially in off-label settings lung infection and patients with neutropenia.

ANTIBIOTIC RESISTANCE – CRITICAL CARE – INFECTIOUS DISEASE – TIGECYCLINE



Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 30,25